We work on developing drugs to slow the progression of dementia. Our work focuses on preventing the spreading of the disease throughout the brain by preventing movement of toxic forms of the tau protein between neurons. Using state-of-the-art stem cell technology, we are identifying extracellular, pathogenic forms of tau. Our goal is to develop therapeutics specifically targeting disease-associated tau to halt disease progression.
The company was founded and is led by Rick Livesey, from the Gurdon Institute, University of Cambridge. In 2016, Gen2 Neuroscience received investment from the Dementia Discovery Fund, an innovative global investment fund launched in 2015 to develop disease-modifying drugs for dementia.